Bank of New York Mellon Corp Sells 10,375 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Bank of New York Mellon Corp lowered its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 162,935 shares of the company’s stock after selling 10,375 shares during the period. Bank of New York Mellon Corp owned about 0.23% of Zentalis Pharmaceuticals worth $494,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals during the third quarter worth $37,000. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the third quarter valued at about $37,000. Ieq Capital LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at about $46,000. Capstone Investment Advisors LLC bought a new position in Zentalis Pharmaceuticals in the third quarter worth about $48,000. Finally, Quarry LP purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at about $55,000.

Zentalis Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ ZNTL opened at $1.79 on Friday. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.61 and a 52 week high of $16.27. The business’s 50 day moving average price is $2.05 and its 200 day moving average price is $2.86. The firm has a market cap of $127.56 million, a P/E ratio of -0.72 and a beta of 1.75.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. As a group, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, Director Jan Skvarka bought 60,000 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Ingmar Bruns purchased 20,000 shares of the stock in a transaction that occurred on Thursday, February 6th. The shares were purchased at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the acquisition, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ZNTL shares. Wells Fargo & Company reduced their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Wedbush reiterated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. UBS Group lowered their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.